Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
|Videos|March 15, 2019
Platinum-Resistant Advanced Ovarian Cancer
Platinum-Resistant Advanced Ovarian Cancer
Advertisement
Case: A 70-Year-Old Woman Presenting With Advanced Ovarian Cancer
H & P:
- A 70-year-old woman presents for evaluation of left-ovary mass discovered during a recent pelvic exam. She reports abdominal tenderness, urinary symptoms, and a “bloated” or “full” feeling, despite normal diet and bowel movements
- Postmenopausal, no children
- PE: reveals a woman of low normal weight (BMI = 19 kg/m2) with hypertension; abdomen is distended and shows dullness to percussion
- BP = 135/80 mm Hg on metoprolol
- Fasting glucose = 95 mg/dL
- LDL = 90 mg/dL
Imaging
- CT with contrast of pelvis, abdomen, and chest reveals multiple peritoneal lesions and spread to outside of liver
- Malignant ascites present
Biopsy and labs:
- Pathology: high-grade epithelioid adenosarcoma, ovarian primary
- BRCA1/2status: unknown
- CA-125: 656 U/mL
Treatment
- She underwent hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and tumor debulking; residual disease after cytoreduction: 1.25 cm
- Diagnosis: stage IV ovarian cancer, grade 3
- Started on carboplatin and paclitaxel plus bevacizumab; achieved a partial response
- She was continued on maintenance bevacizumab
Follow up:
- Follow up imaging at 6 months showed disease progression in the liver
- She was started on paclitaxel plus bevacizumab
Advertisement
Related to this article
The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5